Recent Advances in the Treatment of Combined Small Cell Lung Cancer

DOI: 10.12201/bmr.202607.00001

•  

  Abstract: Combined small cell lung cancer (C-SCLC), as a special subtype of small cell lung cancer (SCLC), is characterized pathologically by the presence of both SCLC and non-small cell lung cancer (NSCLC) components in the tumor tissue, accounting for about 10%-20% of all SCLC cases. Due to its strong pathological heterogeneity and the lack of clinical data, there has long been no standardized treatment protocol. This review systematically summarizes the latest research progress over the past five years on C-SCLC in areas such as pathological diagnosis, molecular mechanisms, treatment strategies (surgery, chemotherapy, radiotherapy, targeted therapy), and prognosis. Studies have found that multidisciplinary treatment (MDT) combined with molecular testing-guided personalized therapy can significantly improve patient outcomes, but issues like chemotherapy resistance and limited targeted therapy options still need to be addressed.

  Key words: combined small cell lung cancer; pathological diagnosis; advances in treatment

  Submit time: 1 July 2026

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• CHENG Ke, XU Shucai. Progress in the treatment of blood hypercoagulability in patients with non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00015

  Zhang Xinzhong. Research progress on folate receptor positive circulating tumor cells and the occurrence and development of non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00024

  李娜, Luo bingqing. Clinical observation of microwave ablation combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer.. 2025. doi: 10.12201/bmr.202504.00054

  付思思. Construction and validation of Nomogram analysis model for nausea and vomiting after lobectomy in non-small cell lung cancer patients. 2025. doi: 10.12201/bmr.202507.00001

  LiuHong, Zhou Xiaoyu, Zhang Qian, TanNianxi. Relationship between DNA methylation of RUNX3, P16 and DAPK gene promoters and chemosensitivity in non-small cell lung cancer. 2025. doi: 10.12201/bmr.202510.00045

  Clinical research progress of PD-1/PD-L1 inhibitor induction therapy in unresectable stage III non-small-cell lung cancer. 2025. doi: 10.12201/bmr.202501.00025

  秦晓宇, FAN Xiangzhen, SA Huanglan, Li Xiaohan, WANG Mingyue, LI Runyu, DING Shutong, NING Fangling. Antiangiogenic Therapy in First-Line Treatment of Advanced NSCLC: Advances in the Immunotherapy Era. 2026. doi: 10.12201/bmr.202605.00079

  Yao Genwu, Wang Yanwei, Guo Jinyi, Li Lulu, Dang Wenbo, Song Ailin. Advances in single-cell sequencing in the breast cancer. 2024. doi: 10.12201/bmr.202407.00053

  HU Wei,. Clinical Efficacy of Penpulimab Combined Chemotherapy in Non-Squamous NSCLC. 2025. doi: 10.12201/bmr.202508.00045

  Li Kesang. Advances in the Diagnosis and Treatment of Cancer of Unknown Primary. 2026. doi: 10.12201/bmr.202606.00008

• ID	Submit time	Number	Download
  1	2026-06-03	10.12201/bmr.202607.00001V1	Download

• Public  Anonymous  To author only Submit Comments